Puma Biotechnology Inc. (PBYI) and Acer Therapeutics Inc. (NASDAQ:ACER) Contrasting side by side

Both Puma Biotechnology Inc. (NASDAQ:PBYI) and Acer Therapeutics Inc. (NASDAQ:ACER) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Puma Biotechnology Inc. 201.52M 5.05 146.96M -3.90 0.00
Acer Therapeutics Inc. N/A 0.00 17.00M -2.01 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Puma Biotechnology Inc. and Acer Therapeutics Inc.


Table 2 shows us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Puma Biotechnology Inc. -72.93% -301.5% -74.1%
Acer Therapeutics Inc. 0.00% -62.9% -57.9%

Volatility & Risk

A -0.13 beta means Puma Biotechnology Inc.’s volatility is 113.00% less than Standard and Poor’s 500’s volatility. Acer Therapeutics Inc.’s 176.00% more volatile than Standard and Poor’s 500 which is a result of the 2.76 beta.


Puma Biotechnology Inc. has a Current Ratio of 3 and a Quick Ratio of 3. Competitively, Acer Therapeutics Inc.’s Current Ratio is 22 and has 22 Quick Ratio. Acer Therapeutics Inc.’s better ability to pay short and long-term obligations than Puma Biotechnology Inc.

Institutional and Insider Ownership

Roughly 95.8% of Puma Biotechnology Inc. shares are held by institutional investors while 58.9% of Acer Therapeutics Inc. are owned by institutional investors. 11.3% are Puma Biotechnology Inc.’s share held by insiders. Competitively, insiders own roughly 24.21% of Acer Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Puma Biotechnology Inc. 3.83% 4.59% -49.57% -50.45% -77.02% -75.59%
Acer Therapeutics Inc. -14.1% -21.03% -35.48% 3.69% 40.37% 42.09%

For the past year Puma Biotechnology Inc. has -75.59% weaker performance while Acer Therapeutics Inc. has 42.09% stronger performance.


Acer Therapeutics Inc. beats on 7 of the 9 factors Puma Biotechnology Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.